Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Viatris (NASDAQ: VTRS) announced that the U.S. Department of Justice (DOJ) no longer considers Mylan, a Viatris subsidiary, and its former President, Rajiv Malik, subjects of an antitrust investigation in the generic drug industry. Additionally, the DOJ's Civil Division will not take further action regarding a civil investigative demand on generic drug pricing and sales. Viatris has consistently maintained that Mylan found no evidence of wrongdoing. The company is now focused on defending itself against remaining civil lawsuits related to these matters. More details are available in Viatris' Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.
Viatris (NASDAQ: VTRS), a global healthcare company, has been named to TIME's inaugural World's Most Sustainable Companies 2024 list. This recognition, presented by TIME and Statista, highlights companies excelling in corporate social responsibility across 30 countries. Viatris was assessed on over 20 sustainability indicators, including greenhouse gas emissions and compliance with international standards. Out of 5,000 companies evaluated, the top 500 were selected.
Lina Andersson, Viatris' Head of Global Sustainability, attributed the accolade to the company's commitment to sustainable operations and reliable global medicine supply. Viatris is a U.N. Global Compact signatory and aims to build sustainable access to medicine. The company has also been recognized on various other prestigious lists, including USA TODAY's America's Climate Leaders and Forbes' World's Best Employers. More details can be found in Viatris' 2023 Sustainability Report.
Viatris (NASDAQ: VTRS), a global healthcare company, has been named to TIME's World's Most Sustainable Companies 2024 list. This recognition, presented by TIME and Statista, acknowledges Viatris' commitment to sustainable practices and corporate social responsibility. Evaluated on over 20 key performance indicators, including greenhouse gas emissions and compliance with international reporting standards, Viatris stands among the top 500 companies from over 30 countries. This accolade reflects Viatris' efforts to maintain a reliable global supply of medicines and its role as a signatory to the U.N. Global Compact. Other recognitions in 2023 and 2024 include listings on USA TODAY's America's Climate Leaders, 3BL's 100 Best Corporate Citizens, and Forbes' World's Best Employers.
Viatris (NASDAQ: VTRS) is set to announce its Q2 2024 financial results on August 8, 2024, before the U.S. market opens. CEO Scott A. Smith and other executives will hold a webcast at 8:30 a.m. ET the same day to discuss the results. The webcast will be accessible live on Viatris' investor relations website, with a replay available afterward. Investors and the public can also join via phone at 844.308.3344 or 412.317.1896 for international callers.
Viatris (NASDAQ: VTRS), a global healthcare company, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami Beach, Florida. CEO Scott A Smith and other executives will represent the company in a scheduled fireside chat at 9:20 a.m. ET.
Interested parties can access a live webcast of the event at the company’s investor relations website, with an archived version available post-event for a time.
Viatris (NASDAQ: VTRS) announced the appointment of Dr. Rogerio Vivaldi Coelho to its Board of Directors as part of its ongoing Board refreshment efforts. Dr. Vivaldi will join the reestablished Science and Technology Committee. He brings extensive experience from his previous roles, including CEO of Sigilon Therapeutics and executive positions at Bioverativ, Spark Therapeutics, and Genzyme. Viatris' Chair, Melina Higgins, and CEO, Scott A. Smith, expressed confidence in Dr. Vivaldi's ability to contribute significantly to the company's growth strategy and innovative pipeline. Dr. Vivaldi emphasized his alignment with Viatris' global vision and commitment to high-quality medicines.
Viatris (NASDAQ: VTRS), a global healthcare company, will participate in the Jeffries Global Healthcare Conference in New York on June 6, 2024. CEO Scott A. Smith and other executives will represent the company in a fireside chat at 8 a.m. ET.
Interested parties can access a live webcast and an archived version post-event at investor.viatris.com.
Viatris has released its 2023 Sustainability Report, emphasizing its commitment to sustainable access to medicine and community health. The report outlines efforts in four areas: Access and Global Health, Our People, Environment, and Community. Notably, the company sold over 80 billion doses of medicine across 165 countries and reached 90% of low- and lower-middle-income countries (LMICs). Initiatives include the Elevate wellbeing program for employees and a 3.7% reduction in greenhouse gas emissions since 2020. The report also highlights the documentary 'Empathy in Africa,' showcasing Viatris' support for healthcare in South Africa and the establishment of the Rhiza Babuyile Clinic. For more details, visit the company's sustainability report online.
Viatris reported strong first-quarter 2024 financial results, including total revenues of $3.66 billion, U.S. GAAP net earnings of $113.9 million, and adjusted EBITDA of $1.19 billion. The company also reaffirmed its 2024 financial guidance ranges and closed several significant transactions, such as the Idorsia transaction and Women's Healthcare Business divestiture. Additionally, Viatris returned $393 million of capital to shareholders in the form of dividends and share repurchases.
Viatris Inc. (NASDAQ: VTRS) will participate in the BofA Securities 2024 Health Care Conference in Las Vegas. CFO Doretta Mistras and CRO Philippe Martin will represent the company in a fireside chat. The event will be live webcasted on investor.viatris.com.
FAQ
What is the current stock price of Viatris Ord Shs (VTRS)?
What is the market cap of Viatris Ord Shs (VTRS)?
